KEQU:NASDAQKewaunee Scientific Corporation Analysis

Kewaunee Scientific (KEQU) is trading at $34.93, just above its 20‑day SMA of $34.36 but still below the 50‑day ($38.15) and 200‑day ($44.27) averages, indicating a short‑term pull‑back within a longer‑term downtrend. The RSI sits at 44, suggesting neutral momentum, while the MACD histogram is positive (+0.24) even though both line and signal are in negative territory, giving a modest bullish tilt. Price is perched near the identified support of $33.70 and faces resistance around $36.07, a range that has constrained moves this week. Volatility is elevated at 45% over the past 30 days and beta exceeds 1.0, underscoring heightened price swings relative to the market. Fundamentally, the stock appears cheap with a trailing PE of 9.4 and a price‑to‑book of 1.42, while the DCF model values the company at roughly $66.4, implying significant upside potential. However, earnings have slipped year‑over‑year despite a 3.3% sales increase, profit margins sit under 4%, and the balance sheet shows a high debt‑to‑equity ratio of 81.8, raising concerns about financial resilience.
The sector—Consumer Cyclical – adds cyclical exposure, and the recent news of a Q3 earnings decline has pressured the share price further, contributing to a 17.5% drop since the release. Volume trends are weakening, with daily volumes near 2,100 against a 10‑day average of 4,550, highlighting liquidity constraints. Given the undervalued valuation, modest growth prospects, and elevated risk factors, the stock may present a contrarian opportunity for investors willing to tolerate price volatility and balance‑sheet risk.